Based on the findings of REACH-2, on 10 May 2019 FDA approved ramucirumab as a single agent to treat HCC patients with AFP concentration ≥400 ng/mL and had prior treatment with sorafenib. This evidence concerns the gene AFP and hepatocellular carcinoma.